Shots:

• Alvotech is eligible to receive ~$450M in gross proceeds including ~$250M from Oaktree trust account, ~$150M common equity PIPE at $10.00/ share, $50M from current Alvotech shareholders making a total enterprise value of ~$2.25B. The transaction is expected to close in H1’22
• The transaction will allow further investment in the Alvotech platform and portfolio to bring cost-effective biosimilars to patients globally. Alvotech currently has seven products in its pipeline across multiple therapeutic areas
• Alvotech will be the 100% equity holder in the combined company. Upon completion of the transaction, the combined company’s securities will trade on NASDAQ under the ticker “ALVO"

/ article | Ref: Businesswire | Image: Alvotech